Drug
FOSTER®
FOSTER® is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
2
50%
Ph phase_4
2
50%
Phase Distribution
0
Early Stage
0
Mid Stage
4
Late Stage
Phase Distribution4 total trials
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
2(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Other(1)
Detailed Status
Completed2
Recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 32 (50.0%)
Phase 42 (50.0%)
Trials by Status
completed250%
recruiting125%
unknown125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_3
Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma
NCT07768891
unknownphase_4
Comparison Efficacy in Patients With Asthma Using Foster MDI and Relvar Medications
NCT04185129
completedphase_3
A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma
NCT00862394
completedphase_4
FACTO Study (Foster® As Complete Treatment Option)
NCT00901368
Clinical Trials (4)
Showing 4 of 4 trials
NCT07768891Phase 3
Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma
NCT04185129Phase 4
Comparison Efficacy in Patients With Asthma Using Foster MDI and Relvar Medications
NCT00862394Phase 3
A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma
NCT00901368Phase 4
FACTO Study (Foster® As Complete Treatment Option)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4